Salarius Pharmaceuticals, LLC
4 clinical trials · Sponsor
◉ Watch Salarius Pharmaceuticals, LLC
| Record | Firm | Date |
|---|---|---|
| Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT05979857) | Salarius Pharmaceuticals, LLC | 2024-03-15 |
| A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) (NCT05266196) | Salarius Pharmaceuticals, LLC | 2022-01-15 |
| Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors (NCT03895684) | Salarius Pharmaceuticals, LLC | 2019-06-25 |
| Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas (NCT03600649) | Salarius Pharmaceuticals, LLC | 2018-06-04 |
Track Salarius Pharmaceuticals, LLC automatically
Every clearance here is in the API, with alerts when new ones post.